Article Details
Retrieved on: 2024-04-08 20:50:23
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
BioNTech announced three-year follow-up data from a Phase 1 trial with the mRNA-based individualized neoantigen-specific immunotherapy, or iNeST, ...
Article found on: www.tipranks.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here